Virologic response to lopinavir-ritonavir-based antiretroviral regimens in a multicenter international clinical cohort: Comparison of genotypic interpretation scores

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 11, 2008, Pages 4050-4056

  Grant, Philip ^a,h   Wong, Eric C ^a   Rode, Richard ^b   Shafer, Robert ^a   De Luca, Andrea ^c   Nadler, Jeffrey ^d   Hawkins, Trevor ^e   Cohen, Calvin ^f   Harrington, Robert ^g   Kempf, Dale ^b   Zolopa, Andrew ^a  

^a STANFORD UNIVERSITY   (United States)

^b ABBOTT LABORATORIES   (United States)

^c CATHOLIC UNIVERSITY   (Italy)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e UNIVERSITY OF NEW MEXICO   (United States)

^f Boston Community Research Initiative of New England   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; INDINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PROTEINASE; RITONAVIR; SAQUINAVIR;

ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; ATU SCORE; COHORT ANALYSIS; COMPARATIVE STUDY; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LPV MUTATION SCORE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; STANFORD DATABASE SCORE; TREATMENT RESPONSE; VIROLOGIC SCORE; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; GENES, VIRAL; GENOTYPE; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; MUTATION; PYRIMIDINONES; RETROSPECTIVE STUDIES; RITONAVIR; YOUNG ADULT;

EID: 55849101120     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00605-08     Document Type: Article

References (19)

1. Benjamini, Y., and Y. Hochberg. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B. 57:289-300.
2. Clotet, B., N. Bellos, J. M. Molina, D. Cooper, J. C. Goffard, A. Lazzarin, A. Wöhrmann, C. Katlama, T. Wilkin, R. Haubrich, C. Cohen, C. Farthing, D. Jayaweera, M. Markowitz, P. Ruane, S. Spinosa-Guzman, E. Lefebvre, and POWER 1 and 2 study groups. 2007. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 369:1169-1178.
3. Dunn, D. T., H. Green, C. Loveday, A. Rinehart, A. Pillay, M. Fisher, S. McCormack, A. G. Babiker, J. H. Darbyshire, and Evaluation of Resistance Assays (ERA) Trial Investigators. 2005. A randomized controlled trial of the value of phenotypic testing in addition to genotypic testing for HIV drug resistance: evaluation of resistance assays (ERA) trial investigators. J. Acquir. Immune Defic. Syndr. 38:553-559.
4. Efron, B., and R. Tibshirani. 1993. Introduction to the bootstrap. Chapman & Hall/CRC Press, Boca Raton, FL.
5. Fox, Z. V., A. M. Geretti, J. Kjaer, U. B. Dragsted, A. N. Phillips, J. Gerstoft, S. Staszewski, B. Clotet, V. von Wyl, and J. D. Lundgren. 2007. The ability of four genotypic interpretation systems to predict virological response to ritonavir-based protease inhibitors. AIDS 21:2033-2042.
6. Hicks, C. B., P. Cahn, D. A. Cooper, S. L. Walmsley, C. Katlama, B. Clotet, A. Lazzarin, M. A. Johnson, D. Neubacher, D. Mayers, H. Valdez, and RESIST investigator group. 2006. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the randomized evaluation of strategic intervention in multi-drug resistant patients with tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 368:466-475.
7. Johnson, M., G. Beatriz, C. Rodriguez, J. Coco, E. DeJesus, A. Lazzarin, K. Lichtenstein, A. Rightmire, S. Sankoh, and R. Wilber. 2005. Atazanvir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virologic failures. AIDS 19:685-694.
8. Johnson, V. A., F. Brun-Vezinet, B. Clotet, H. F. Günthard, D. R. Kuritzkes, D. Pillay, J. M. Schapiro, and D. D. Richman. 2007. Update of the drug resistance mutations in HIV-1: 2007. Top. HIV Med. 15:119-125.
9. Kempf, D. J., J. D. Isaacson, M. S. King, S. C. Brun, J. Sylte, B. Richards, B. Bernstein, R. Rode, and E. Sun. 2002. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antivir. Ther. 7:165-174.
10. Kempf, D. J., J. D. Isaacson, M. S. King, S. C. Brun, Y. Xu, K. Real, B. M. Bernstein, A. J. Japour, E. Sun, and R. Rode. 2001. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J. Virol. 75:7462-7469.
11. King, M. S., R. Rode, I. Cohen-Codar, V. Calvez, A.-G. Marcelin, G. J. Hanna, and D. J. Kempf. 2007. Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients. Antimicrob. Agents Chemother. 51:3067-3074.
12. Madruga, J. V., D. Berger, M. McMurchie, F. Suter, D. Banhegyi, K. Ruxrungtham, D. Norris, E. Lefebvre, M. P. de Béthune, F. Tomaka, M. De Pauw, T. Vangeneugden, S. Spinosa-Guzman, and TITAN study group. 2007. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 370:49-58.
13. Mocroft, A., S. Vella, T. L. Benfield, A. Chiesi, V. Miller, P. Gargalianos, A. d'Arminio Monforte, I. Yust, J. N. Bruun, A. N. Phillips, J. D. Lundgren, et al. 1998. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 352:1725-1730.
14. Palella, F. J. J., K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman, S. D. Holmberg, et al. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338:853-860.
15. Panel on antiretroviral guidelines for adults and adolescents. 29 January 2008, posting date. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, Washington, DC. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL. pdf.
16. Parkin, N., C. Chappey, and C. Petropoulos. 2003. Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance. AIDS 17:955-961.
17. Walmsley, S., B. Bernstein, M. King, J. Arribas, G. Beall, P. Ruane, M. Johnson, D. Johnson, R. Lalonde, A. Japour, S. Brun, E. Sun, and M98-863 Study Team. 2002. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N. Engl. J. Med. 346:2039-2046.
18. Zolopa, A., H. Rice, J. Nadler, J. Schaenman, T. Hawkins, C. Cohen, R. Rode, and D. Kempf. 2003. Genotypic predictors of response to lopinavir/ritonavir in clinical practice, abstr. no. 823. Second Int. AIDS Soc. Conf. HIV Pathog. Treat., Paris, France, 13 to 16 July 2003.
19. Zolopa, A. R., R. W. Shafer, A. Warford, J. G. Montoya, P. Hsu, D. Katzenstein, T. C. Merigan, and B. Efron. 1999. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann. Intern. Med. 131:813-821.